Trevi Therapeutics (TRVI) Expected to Release Earnings on Monday

Trevi Therapeutics (NASDAQ:TRVI) is expected to be releasing its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect the company to announce earnings of ($0.1317) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:30 PM ET.

Trevi Therapeutics (NASDAQ:TRVI) last issued its earnings results on Thursday, August 6th. The company reported ($0.11) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.11). On average, analysts expect Trevi Therapeutics to post ($0.48) EPS for the current fiscal year and ($0.62) EPS for the next fiscal year.

Trevi Therapeutics Trading Down 1.7%

Shares of TRVI traded down $0.23 during trading hours on Wednesday, reaching $13.63. The stock had a trading volume of 223,275 shares, compared to its average volume of 1,792,198. The firm has a 50-day simple moving average of $14.52 and a 200 day simple moving average of $14.34. Trevi Therapeutics has a 12 month low of $9.82 and a 12 month high of $20.22. The company has a market capitalization of $1.94 billion, a price-to-earnings ratio of -40.07 and a beta of 1.15.

Insider Transactions at Trevi Therapeutics

In related news, Director Michael Heffernan sold 39,473 shares of the stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $15.09, for a total value of $595,647.57. Following the completion of the sale, the director directly owned 6,351 shares of the company’s stock, valued at approximately $95,836.59. This represents a 86.14% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 15.39% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on TRVI shares. Cantor Fitzgerald upped their price objective on shares of Trevi Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Morgan Stanley reiterated an “overweight” rating and set a $23.00 price objective on shares of Trevi Therapeutics in a report on Friday, August 7th. Raymond James Financial reissued a “strong-buy” rating and set a $40.00 target price on shares of Trevi Therapeutics in a research report on Friday, August 7th. B. Riley Financial upped their target price on shares of Trevi Therapeutics from $21.00 to $31.00 and gave the stock a “buy” rating in a report on Monday, July 20th. Finally, Wall Street Zen cut shares of Trevi Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $27.08.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for chronic conditions that have limited therapeutic options. The company’s lead product candidate is Haduvio, an oral extended-release formulation of nalbuphine, an opioid receptor modulator designed to combine kappa-opioid receptor agonism with mu-opioid receptor antagonism.

Trevi is evaluating Haduvio in conditions involving chronic cough and severe itching. Its clinical development programs have included studies in chronic cough associated with idiopathic pulmonary fibrosis, a progressive lung disease, and chronic pruritus associated with systemic sclerosis, an autoimmune connective-tissue disorder.